Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13363
UPID:
CTBP1_HUMAN
Alternative names:
-
Alternative UPACC:
Q13363; Q4W5N3; Q7Z2Q5
Background:
C-terminal-binding protein 1 plays a pivotal role in various cellular processes, including acting as a corepressor for transcription regulators like GLIS2 or BCL6. It exhibits dehydrogenase activity and is crucial in maintaining the balance between tubular and stacked structures in the Golgi complex. Additionally, it is instrumental in the differentiation of brown adipose tissue (BAT).
Therapeutic significance:
The protein is linked to Hypotonia, ataxia, developmental delay, and tooth enamel defect syndrome, an autosomal dominant disorder. This association highlights its potential as a target for therapeutic intervention in treating or managing this syndrome.